PARP Inhibitors for Cancer Therapy

descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 2017 English Publisher:Elsevier BVJournal:Cell, volume 169, page 183 (issn: 0092-8674,

Copyright policy )

Authors: Ken Y, Lin; W Lee, Kraus;

doi: 10.1016/j.cell.2017.03.034

pmid: 28388401

PARP Inhibitors for Cancer Therapy

- Summary
- Subjects
- Metrics

Abstract

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

Related Organizations

The University of Texas Southwestern Medical Center
United States

Keywords

BRCA2 Protein, Ovarian Neoplasms, Indoles, BRCA1 Protein, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Mutation, Humans, Female, Drug Approval

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	93
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%